In plain terms

The claim being assessed: Systemic menopausal hormone therapy causes a reduction in bothersome vasomotor symptoms in perimenopausal and postmenopausal women.

Where the evidence stands: Ζ — Several independent lines agree. Different kinds of evidence, which could not all be wrong for the same reason, point the same way.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Leading among models compared

What this review means

Systemic menopausal hormone therapy reduces bothersome hot flushes; this established symptom benefit does not demonstrate dementia or cardiovascular prevention, and testosterone needs its own indication-specific evidence.

Implications for health and treatment: The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy.

Limits for individual care: 64 primary reports with 8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 64 primary reports; claims: 70; verified: 70; unverified: 0. Verification is bounded attribution. Access: 8 partial-body and 56 bounded abstract/status examinations. Literature cutoff: 2026-10-12; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 5 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Systemic menopausal hormone therapy reduces bothersome hot flushes; this established symptom benefit does not demonstrate dementia or cardiovascular prevention, and testosterone needs its own indication-specific evidence.

Deciding experiment: Run a prospectively registered, adequately powered symptomatic-menopause trial of a measured systemic estradiol regimen, placebo and a mechanistically distinct nonhormonal comparator, with identical contact, allocation-guess checks, objective thermal/skin-conductance sensing and daily patient-important symptoms. Embed baseline-defined age/stage and route strata and a blinded randomized-withdrawal phase; test the hypothesized mediator without conditioning on response. A separate long-horizon contemporary-regimen prevention trial is required for SC3.

Belief versus evidence: The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy.

Best-supported rival: Nonhormonal thermoregulatory pathway modulation (rank 2) — the nominal, sex-steroid replacement, itself ranks first, so it is not its own rival. MsFLASH PMID24861828 shows estradiol and the nonhormonal venlafaxine both outperform placebo, with an imprecise active-treatment difference. It distinguishes genuine pathway-sensitive relief from an exclusive nonspecific account; it does not prove hormone replacement is universally superior to NK3 antagonism. The first two models are compatible therapeutic accounts, and their ordering follows the registered MHT claim rather than an unperformed direct hormone-versus-NK3 trial.

COMPETING MECHANISTIC MODELS

Rank 1: Sex-steroid replacement reduces hormone-withdrawal symptoms (Ζ). Replacing sex-steroid signaling reduces vasomotor symptoms in enrolled symptomatic women. Placebo-controlled oral/transdermal trials, an objective sweating-threshold prediction and concordant withdrawal observations favor real biological symptom control. Variable response, symptom-free low-estrogen women and nonhormonal efficacy defeat sole-cause/necessity claims; symptom relief does not establish prevention.

Rank 2: Nonhormonal thermoregulatory pathway modulation (Ζ). NK3 and related thermoregulatory interventions relieve the same vasomotor phenotype without systemic hormone replacement. NKB blinded challenge and NK3 antagonist controlled trials connect pathway perturbation to objective flushing and clinical symptoms; OASIS3 adds a distinct dual-neurokinin intervention. MOONLIGHTI was null at its tested dose/context, liver and other adverse outcomes require separate assessment, and the full hormone–KNDy mediator chain remains unisolated.

Rank 3: Tissue, receptor and route effects separate indications (Ε). Hormone effects depend on tissue, regimen and baseline context, allowing symptom benefit alongside different vascular, cognitive and sexual effects. WHI separate regimens, ELITE timing-dependent CIMT and testosterone domain/dose trials demonstrate mapped endpoint/context differences. These contrasts do not identify every mediator, and a unified model cannot claim prospective risk prediction for every modern formulation.

Rank 4: Expectancy and spontaneous fluctuation (Β). Placebo response, regression and natural symptom fluctuation explain part of apparent improvement. Substantial placebo changes in MsFLASH and modern trials, attenuated KEEPS group differences and uncontrolled clinic cohorts support this contribution. Randomized active-treatment differences and objective physiological effects contradict an exclusive reporting-only account; placebo-arm change does not itself randomize expectancy versus natural recovery.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Systemic menopausal hormone therapy causes a reduction in bothersome vasomotor symptoms in perimenopausal and postmenopausal women.

The nominal is the clinical sufficiency proposition represented by SC2. Mechanism, superiority, additional indication and safety subclaims are separately reported and do not gate the registered efficacy claim. The original topic family and this narrower gradeable restatement are retained; no response-based exclusions are allowed.

Selection: position 3 among the first five editorial traffic-priority families, registered on 2026-10-12. First five editorial traffic-priority families in health_topic_traffic_priority_2026-10-12/ranking.json; traffic proxies are not measured worldwide popularity or a preassigned verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: The frozen seven rubrics have no dedicated menopause or endocrine-treatment rubric. Rubric06 is routed for endocrine physiology and functional clinical outcomes, and rubric07 supplies subjective-endpoint/comparator safeguards. Literal lifespan criteria are quoted unchanged but do not describe this non-lifespan claim. The preregistered adaptation substitutes measured vasomotor symptom frequency/severity and interference for aging trajectories; active hallucination-matched controls are not required for an intervention without unmistakable acute hallucinogenic effects. This limits cross-topic comparability and is not a change to the frozen ladder or universal caps.

The nominal is a therapeutic symptom proposition, not a score for every use of hormones in women. Oral estradiol trials (PMIDs10993030,16735941), transdermal dose studies (3928674), PEPI (9840563), REPLENISH (29889748) and MsFLASH (24861828) supply direct randomized symptom evidence. Placebo changes are substantial, so improvements from baseline alone exaggerate benefit. In MsFLASH both estradiol and venlafaxine outperformed placebo; its imprecise between-active-arm contrast cannot establish universal hormone superiority.

The hormone–thermoregulatory mechanism has more than a hormone-level correlation. Randomized estradiol changed the sweating threshold and objectively recorded flushing (11872200). Induced ovarian suppression produced hot flashes but not uniform depression (23545794), while symptomatic/asymptomatic physiological comparisons (10411797,15772562) show that low estrogen alone does not define who flushes. Blinded NKB challenge and NK3 blockade (25683060,28385352) give a downstream pathway alternative. They narrow biology; they do not prove that replacement is necessary for all relief or that every menopausal complaint shares one mediator.

Disease prevention requires different outcomes. The separate oral-regimen WHI trials (12117397,15082697) and later original follow-up (24084921) show mixed benefits/harms rather than net cardiovascular prevention. WHIMS (12771112,15213206) did not demonstrate dementia prevention in older enrolled women. ELITE (27028912,27421538) illustrates why earlier-start CIMT effects do not confer cognitive or hard-event benefit. KEEPS (26035291) supplies younger modern-route cognitive nulls alongside symptom relief. Large Medicare associations (38595196) form a legitimate countercase but retain prescribing and healthy-user confounding. Neither ignoring observational results nor treating them as randomized prevention is justified.

Testosterone has its own indication. APHRODITE (18987368), ADORE (20166859) and INTIMATE studies support modest sexual-function benefit in diagnosed postmenopausal HSDD, with dose, endpoint and concurrent-estrogen limits. Open-label extensions (21142609) cannot settle rare long-term harms. A selective verbal-learning signal (24716847) coexists with multiple cognitive/fatigue nulls (20667535,25430996,23095007) and a study in which all arms received testosterone (16837882); the latter cannot prove testosterone efficacy from within-group improvement. High-exposure muscle signals (24281237) require their dose and function boundaries. The clinic cohort (39283522) is a hypothesis-generating association, not proof of broad wellbeing benefit.

Consensus was an additional search and reconciliation tool. Its observed automatically generated From2014 filter omitted older WHI/WHIMS, thermoregulatory and HSDD originals despite the explicit query; its coverage matrix is therefore not a count of all examined evidence or proof of missing literature. Provider statements about blinding, endometrial zero events and transdermal superiority require original design/denominator checks. Corrections attached to the 2025 WHI secondary analysis remain visible; unexamined correction details are not silently treated as verified numerical claims.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy. Sensitivities: weakest-link Β; primary-subclaim Ζ; scope-matched Ζ.

Decisive-perturbation inventory and causal tally

[14] Extended WHI analyses retain vasomotor benefit but divergent clinical risks and benefits; neither regimen improved overall mortality. Two parent randomized trials generate many reports; oral CEE regimens cannot be transferred wholesale to other routes or younger indications.

[19] APHRODITE found modest sexual-function benefit at the higher tested testosterone patch dose in postmenopausal HSDD women without estrogen. Lower dose missed the event-frequency endpoint; androgenic events increased and rare breast outcomes cannot settle long-term risk.

[31] A randomized transdermal testosterone trial improved its verbal-learning task but not other cognitive domains or general wellbeing. One modest task-specific signal is neither prevention of dementia nor evidence of generalized energy and muscle benefits.

[34] A testosterone dose-ranging trial found no benefit across tested cognitive domains over twenty-four weeks despite verified exposure. Only participants with complete cognitive data were analyzed; small dose groups limit precision and share a parent with muscle outcomes.

[36] Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo. Small physiological trial narrows diary expectation but does not prove the complete estrogen–KNDy mediator sequence or all individual responses.

[42] Blinded neurokinin-B infusion caused flushing with objective heat-dissipation changes in healthy women without measured estradiol change. Exogenous challenge is a pathway sufficiency test, not proof hormone withdrawal or endogenous NKB is necessary in every menopausal flush.

[43] A blinded NK3-antagonist crossover trial reduced menopausal hot-flush frequency compared with placebo. Small sample, incomplete completion and liver-enzyme elevations limit broad efficacy and safety predictions; it tests a nonhormonal pathway.

[57] ELITE slowed carotid intima-media progression only with early estradiol initiation, without corresponding coronary CT differences. Surrogate progression and sparse clinical events do not establish net cardiovascular or dementia prevention.

[58] ELITE cognitive outcomes showed no verbal-memory, executive or global-cognition benefit with early or later estradiol initiation. Several years of cognitive tests cannot exclude later dementia prevention; same parent as the vascular report.

[59] KEEPS showed vasomotor relief but no cognitive benefit; oral CEE improved selected mood scores while transdermal estradiol did not. Cognitively healthy low-risk recent-menopause users, attrition and finite horizon constrain disease-prevention inference.

[61] MsFLASH randomized estradiol and venlafaxine both reduced bothersome vasomotor frequency more than placebo. The between-active-treatment contrast was imprecise; short follow-up cannot establish general hormone superiority or disease prevention.

[62] REPLENISH tested oral estradiol/progesterone versus placebo and found vasomotor-frequency/severity benefit at several doses. Dose-specific coprimary results and finite endometrial analysis population do not prove zero lifetime risk; attached correction details require separate checking.

[63] Testosterone dose-ranging produced lean-mass and selected muscle-power gains mainly at supraphysiologic exposure, with several physical-function tests unchanged. Small dose groups, secondary outcomes and late trial registration limit prediction; high-dose gains cannot establish physiological replacement benefit.

Tally: 15 positive qualifying study units across scoped subclaims; 42 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Repeated parent-trial reports, pooled analyses, extensions and hormone correlations cannot add causal study units. Positive qualifying within-scope symptom/HSDD/task studies are not proof of general prevention or all-indication efficacy. The objective physiological prediction narrows a different measurement failure; other hormone trials replicate the same clinical allocation line.

Cap audit, precedence and Β/Γ/Δ boundary

Under the prospectively declared clinical adaptation, hormone randomization crosses Δ for symptom outcomes in the population and horizon tested. Human-only clinical efficacy is not extrapolated from model organisms and is not a claim of slowed aging. Association, hormone-level changes and CIMT alone retain their respective Β/Γ inference ceilings. Null randomized prevention and cognitive trials do not earn positive crossings. The convergent symptom set is not re-capped on its observational withdrawal component, and same-parent reports are grouped.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: Rubric06 single-species/strain aging ceiling is not imposed on a direct human symptomatic-treatment claim under the declared clinical adaptation; model-only and biomarker-only inferences remain restricted. Rubric07 open-label and mediation-by-correlation rules restrict the testosterone clinic cohort and statistical mediator claims. No unmistakable acute hallucinogenic effect is asserted for hormone therapy; absence of allocation-guess measurement remains an uncertainty rather than an invented proof of maintained blinding. A positive clinical trial does not establish prevention, necessity, all-dose response or long-term safety.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Hormone suppression and replacement, a predicted thermoregulatory response under randomized estradiol and mechanistically distinct NKB challenge/blockade support a causal endocrine–thermoregulatory contribution. Deficiency alone does not predict all symptoms; objective pathway tests and symptomatic/asymptomatic comparisons preserve this boundary. Ζ is contribution, not sole-cause necessity.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Repeated blinded hormone trials show symptom relief beyond placebo in baseline symptomatic women, including oral and transdermal regimens. MsFLASH provides an active nonhormonal comparison; objective sweating-threshold/flush experiments reduce a reporting-only explanation, and withdrawal observations agree with reversible control. Ζ reflects complementary failure structures; replication/report counts alone do not provide independence. Η would require stronger mediator isolation and prospective cross-context control of major exceptions.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Net cardiovascular or neurodegenerative prevention does not inherit symptom efficacy. WHI/WHIMS and WISDOM supply direct regimen/age-specific clinical contradictions, while early ELITE CIMT and Medicare associations leave a narrower preventive possibility open. Positive surrogate/observational support is insufficient for hard prevention; the functional contradiction downgrades that supportive Γ-level route to Β. It is not a blanket claim all formulations or early symptomatic use are harmful.

SC4 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: yes. Testosterone patch trials establish a modest causal sexual-function benefit in baseline diagnosed postmenopausal HSDD, with limits across dose, concurrent estrogen and endpoints. These replicated, closely related intervention platforms do not supply a separate orthogonal causal mechanism or all-women indication; Ε preserves the mapped clinical context and finite safety horizon.

SC5 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. One verbal-learning outcome and high-exposure muscle/performance signals provide narrower clinical positives; these are retained with their doses and populations. They do not establish the bundled general cognition, energy and muscle proposition in women without HSDD. Multiple cognitive domains and wellbeing/fatigue outcomes are null. The full enhancement proposition retains partial support at Γ; this does not deny the separate HSDD clinical efficacy or the isolated task finding.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Controlled endocrine suppression/restoration and independently measured thermoregulatory challenge responses test a causal contribution of sex-steroid withdrawal. NK3 challenge/blockade narrows downstream circuitry but is not by itself proof steroid withdrawal is necessary or sufficient for every flush. Objective heat-dissipation events distinguish physiology from a hormone concentration proxy.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): For the registered therapeutic proposition, blinded randomized systemic hormone treatment versus credible placebo or a nonhormonal active arm, with enrollment symptoms and measured subsequent symptom frequency/severity, is the human clinical equivalent. This is meaningful symptom function within a fixed horizon, not lifespan extension; hormone level changes alone do not qualify. Clinical diary trials are replicated one pharmacological line, while a predicted sweat-threshold/physiological-flush response measured independently of diaries narrows a specific reporting-error alternative.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): The claimed net prevention requires incident cardiovascular disease, dementia and integrated clinically important benefits/harms over years. CIMT, metabolic markers, cognitive test performance and symptom relief are not interchangeable with prevention of these diseases. Negative randomized clinical endpoints are informative discriminators but never positive threshold crossings.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Blinded randomized testosterone allocation with baseline diagnosed HSDD, measured desire, distress and satisfying sexual function tests this indication. The subjective clinical phenotype is the stated endpoint; blood testosterone is target engagement rather than efficacy. Trials using the same patch and sexual diary platform form a replicated line, not several mechanistically independent modalities.

SC5 applied rubric adaptation (distinct from the unchanged literal criterion): Specific cognitive tasks, measured muscle performance and patient-important energy/function must be kept separate. A task-specific benefit in a controlled trial and muscle effects at supraphysiologic doses establish bounded contexts, not generalized wellbeing at physiological replacement doses. No positive HSDD result is inherited by nonspecific domains.

SC1 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC1 literal Γ hard rule: “Single-species or single-strain evidence” The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species.

SC1 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication.

SC2 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC2 literal Γ hard rule: “Single-species or single-strain evidence” The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species.

SC2 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication.

SC3 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC3 literal Γ hard rule: “Single-species or single-strain evidence” The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species.

SC3 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication.

SC4 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC4 literal Γ hard rule: “Single-species or single-strain evidence” The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species.

SC4 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication.

SC5 literal Γ hard rule: “ROS change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “NAD level change measurements alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Mitochondrial metrics alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Senescence marker changes alone” Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale.

SC5 literal Γ hard rule: “Single-species or single-strain evidence” The lifespan-specific animal rule is explicitly adapted for direct human clinical trials; a symptom indication does not require extending lifespan or testing humans as multiple species.

SC5 literal Γ hard rule: “Biomarker-only improvement without organismal benefit” Isolated hormone, lipid, bone or vascular-marker movement retains Γ for a hard clinical prevention/function inference; symptom or sexual-function outcomes are considered under their own indication.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC1 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC1 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: yes.

SC1 Η: “Requires: - Robust cross-context intervention evidence - Mechanistic specificity - Strong alignment of lifespan/healthspan outcomes” Satisfied: no. A selective, reversible human endocrine/thermoregulatory mediation experiment must demonstrate how steroid withdrawal alters measured downstream circuitry and symptoms, with objective sensing, allocation-guess checks and symptomatic/asymptomatic baseline contrasts.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC2 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC2 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: yes.

SC2 Η: “Requires: - Robust cross-context intervention evidence - Mechanistic specificity - Strong alignment of lifespan/healthspan outcomes” Satisfied: no. A prospectively powered cross-context comparison should combine objective and patient-important symptoms, verified exposure, independent instruments and allocation-guess assessment, isolate the hormone-mediated dependency and replicate major age/formulation exceptions. This would support Η; reliable prospective individual prediction is needed for Θ.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A randomized early-initiation contemporary-regimen trial must demonstrate net reduction in hard cardiovascular or incident dementia outcomes, with complete harm ascertainment; surrogate improvement and observational continuation are insufficient.

SC4 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: yes.

SC4 Ε: “Requires causal effect in constrained contexts, backgrounds, or species.” Satisfied: yes.

SC4 Ζ: “Requires: - Reproducible intervention effects - Mechanistic narrowing - Evidence not reducible to general sickness, caloric reduction, or developmental artifacts” Satisfied: no. Independent mechanistic manipulation or a distinct failure-resistant causal modality should support HSDD benefit beyond patch/sexual-diary replication, with prespecified physiological exposure and longer controlled safety follow-up.

SC5 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Replicate patient-important cognition, fatigue/energy and muscle function at physiologic female exposure in baseline-defined women without HSDD; task-only, high-dose or lean-mass-only effects cannot establish the generalized package.

Upper ladder: The upper ladder is reachable for direct human clinical claims after the declared phenotype adaptation. Replicated symptomatic hormone intervention and an independently instrumented thermoregulatory prediction permit Ζ, with suppression/withdrawal complementary context. Η is held because the complete mediator dependency and major age/regimen exceptions are not prospectively isolated; Θ requires predictive response performance and Ω requires necessity and sufficiency, which nonhormonal relief directly challenges for any exclusive replacement model. No deliberate universal-aging RCT is demanded. The generic hard-endpoint therapeutic equivalent is available in prevention trials, but null or harmful prevention results do not positively support that hypothesis. GnRH suppression is an imposed intervention, not a natural experiment; no genetic instrument or fully blinded withdrawal-and-rechallenge line is asserted.

Independence: Ζ is not awarded for different sponsors, routes, sites or papers alone. The symptom RCT platform is one replicated pharmacological line; the instrument-independent thermal prediction addresses its diary-reporting failure mode, with induction/withdrawal only complementary because of uncontrolled exposure or unblinding. Downstream NKB challenge/blockade applies principally to SC1 and the nonhormonal model. WHI/WHIMS, REPLENISH, ELITE, testosterone dose-response and interview/extension reports share parent studies. Shared pharmacology, subjective endpoints and limited blinding-integrity measurement remain explicit limitations.

Blinded symptom-allocation trials [61, 2, 62]: Random allocation reduces treatment-selection and spontaneous-regression confounding; different hormone trials are replications of this line and share diary/expectancy risks.

Predicted thermoregulatory effect measured independently of symptom diaries [36, 37]: A prospectively tested sweating-threshold response with laboratory skin-conductance flushing is not manufactured by diary misreporting alone. Thermal challenge and a different measurement instrument narrow that specific error, while common hormone pharmacology and autonomic expectancy remain shared concerns.

Orthogonal downstream NKB challenge and NK3 blockade [42, 43]: A neuropeptide challenge and receptor antagonism reverse different pathway directions using objective and clinical endpoints. This supports SC1/M2 circuitry and narrows an exclusive expectancy account; it does not add an extra MHT efficacy trial to SC2.

Falsification and pitfalls

Pathway manipulation changes biomarkers but not lifespan/healthspan. For SC3, the declared clinical prevention adaptation is triggered by ELITE surrogate support without hard prevention demonstration, together with WHI/WHIMS functional contradictions. The supportive surrogate route cannot rescue net prevention. Additional downgrade: True.

Mechanism conflation. Vasomotor benefit, dementia/cardiovascular prevention, HSDD treatment and generalized testosterone enhancement are separate subclaims.

Confirmation by biomarker. CIMT, hormone levels and metabolic markers cannot stand in for net clinical prevention or subjective wellbeing.

Replication confused with causal-line independence. Routes, sponsors, repeated WHI/REPLENISH reports and multiple doses do not create independent modalities.

Scope fitted to the result. Symptoms, HSDD, age and regimen are defined before outcomes; retrospective responders are not a valid scope.

Negative field-valid perturbation read as a crossed threshold. WHIMS, ELITE cognition, testosterone domain nulls and MOONLIGHTI remain discriminators rather than positive causal support.

Adversarial steelman: above, then below

One rung above, Η: systemic hormone treatment repeatedly changes symptomatic trajectories, across oral and transdermal routes, with laboratory physiology and loss of benefit after cessation; the clinical claim is modest and well replicated. This is the strongest case for strong convergent intervention-sensitive evidence without demanding a lifespan outcome. The blocker is incomplete mediator isolation and quantified cross-context/blinding control, not the existence of WHI prevention harms in a separately scoped proposition.

One rung below, Ε: all positive clinical trials could be classified as one hormone modality with related subjective measurement, the physiological experiment is small, and withdrawal reports are selected/unblinded. This is a serious independence objection. The objective predicted thermoregulatory response measured outside diary reporting narrows a different systematic error; under the preregistered human clinical adaptation this plus controlled symptom allocation supports Ζ, with no claim that route/sponsor replication alone adds lines.

Retain Ζ for the clinical symptom claim, while exposing the clinical-rubric adaptation and the independence hinge. Reject Η pending mediation and prospective context checks. Reject Ε as the nominal because the separately instrumented, predicted physiological response complements randomized clinical symptom outcomes; retain Ε for the bounded testosterone indications/domains where analogous orthogonal convergence is absent. Prevention remains Β after its own contradictory clinical evidence.

Final score, causal direction and M/S/D

The registered primary-subclaim rule assigns Ζ with High confidence from SC2: systemic menopausal hormone therapy causes vasomotor symptom relief in baseline symptomatic women. Endocrine–thermoregulatory contribution is separately rated Ζ, prevention Β, testosterone for HSDD Ε, and broader testosterone enhancement Γ. Weakest-link would return Β for an unregistered conjunction of these different indications; primary-subclaim and scope-matched return Ζ. The symptom grade does not establish preventive or testosterone efficacy.

Menopausal ovarian transition lies upstream. Hormone replacement modulates and stabilizes thermoregulatory signaling and the relief trajectory; it is not necessary for all relief, since venlafaxine/NK3 blockade also work, and hormone deficiency alone does not initiate flushing in every woman. Directional steps1/2 do not fit an inert downstream marker, step3 does not meet universal initiation/necessity/rate-limiting requirements, and step4 cannot establish necessity. Step5 therefore supplies the limited stabilizing role, not a sole primary driver of all menopausal disease.

Momentum: Mechanistic only. The named artifact is the completed controlled neurokinin-pathway programme, OASIS3 (PMID40920404) and the earlier NK3 trials, plus comparative symptom studies; these test a nonhormonal pathway and specific treatment choices. No trial addressing this subclaim's boundary check — isolation of the hormone-mediated mediator with prospective cross-context control — was identified as underway, consistent with the Stability entry below. No unverified named pending cardiovascular trial is asserted.

Stability: Stable. No verified pending result was identified that is likely to overturn the replicated short-horizon MHT symptom claim. A large prespecified objective/subjective trial with credible maintained blinding showing loss of active benefit would lower the grade; a mediator-isolation/replicated-context study could raise it, but these are proposed rather than falsely declared ongoing named triggers.

Divergence: Aligned. Scoped original clinical framing implies Ζ and assessed Ζ; 5 minus 5 = 0. This does not measure all social-media hormone narratives or imply aligned prevention claims. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Run a prospectively registered, adequately powered symptomatic-menopause trial of a measured systemic estradiol regimen, placebo and a mechanistically distinct nonhormonal comparator, with identical contact, allocation-guess checks, objective thermal/skin-conductance sensing and daily patient-important symptoms. Embed baseline-defined age/stage and route strata and a blinded randomized-withdrawal phase; test the hypothesized mediator without conditioning on response. A separate long-horizon contemporary-regimen prevention trial is required for SC3.

Readout: Prespecified symptom frequency, severity and daily interference over 4–24 weeks, concordant independently sensed heat-dissipation episodes and reversible withdrawal response; prevention uses incident cardiovascular disease/dementia and complete benefit/harm composites. Controls: Intention-to-treat analysis, measured exposure, identical contact, credible placebo/comparator, prospective strata, missing-data sensitivity, independently blinded physiological assessors and no responder exclusions. Supporting: Persistent hormone-allocation effect beyond reporting/expectancy artifacts, concordant thermal physiology and reversible mediated response across registered strata would strengthen the clinical grade; hard net event reduction is separately needed for prevention. Falsifying: An adequately engaged trial losing symptom benefit against maintained blinding and independent objective measures would lower the clinical grade; improved markers without hard-event benefit would leave prevention unestablished.

KNOWLEDGE GAPS

The complete endocrine-to-thermoregulatory mediator sequence is not isolated by ordinary efficacy trials.

Allocation-guess assessment and objective symptom sensing are incompletely integrated in large hormone trials.

Long-term hard endpoints for contemporary transdermal estradiol/micronized progesterone begun near menopause need direct assessment rather than extrapolation from oral CEE/MPA or observational continuation.

Physiological-dose testosterone requires replicated patient-important nonspecific cognition, fatigue and muscle-function endpoints; supraphysiologic dose signals do not establish ordinary replacement benefit.

Rare breast, vascular and liver harms require formulation-specific long-term surveillance and cannot be excluded by small short trials.

REVIEWER NOTES

Original primary abstract/status passages and selected Methods/Results from eight accessible bodies were actually examined, with receipts. Most full papers and supplements were not audited. A public ELITE cognition PMC retrieval returned no body and remains abstract-only. Framework adaptation and the Ζ independence hinge are explicit judgments for coordinator review, not blinded scientific peer review. Provider search counts and graphics are not reproduced as primary evidence. Scite monthly quota was previously exhausted and no fresh Scite query is claimed. Coordinating review retained Ζ/High for the exact vasomotor symptom claim, restricted bundled nonspecific testosterone enhancement to Γ and assigned per-subclaim confidence. Withdrawal evidence remains complementary; the independence list excludes it as a clean line. The separately instrumented thermoregulatory prediction narrows diary-reporting bias while hormone pharmacology remains shared.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Consensus correctly distinguishes estradiol and venlafaxine placebo contrasts from their imprecise direct comparison. Selected original Methods confirm baseline bothersome symptoms, identical pills, randomization and diary-defined primary frequency; Results show both active arms improve that endpoint. The small between-active difference does not prove broad hormone superiority. Original PMID24861828.

Consensus identifies the right primary symptom and endometrial endpoints. The examined original abstract distinguishes dose-specific frequency and severity success and separates medication-exposed, endometrial-analysis and symptom-substudy populations. Its assertion that the endometrial analysis count simply represents completion is unsupported. The attached correction was identified; no universal zero-risk inference is used. Original PMID29889748.

Consensus calls REPLENISH double-dummy blinding maintained. The examined original primary abstract establishes a randomized double-blind single-capsule trial, but does not document allocation-guess performance. A design label cannot verify actual maintained masking, and no invented double-dummy or blinding-integrity check is credited. Original PMID29889748.

Consensus appropriately separates symptom benefit from prevention but relies heavily on this later WHI report. Its linked parent has two attached corrections concerning text/supplement and Figure 3. Correction identities were checked, while substantive details remain unavailable in the examined passages, so numerical subgroup claims are withheld. This report remains grouped with the original WHI parents rather than counted as a new independent trial. Original PMID40952729.

The observed Consensus search applied a From2014 filter and did not provide the older WHIMS original requested. The independently examined original randomized report shows probable dementia increased with the tested combined regimen among women enrolled aged at least sixty-five. Its age/regimen scope is retained; this is neither proof all modern therapy has the same risk nor evidence of dementia prevention. Provider omission does not erase the original study. Original PMID12771112.

Consensus highlights KEEPS symptom relief and discusses transdermal superiority via a network meta-analysis. Selected KEEPS original Methods/Results show both hormone routes reduce symptoms, but cognition does not improve and mood effects differ by route. A network ranking or absent head-to-head superiority result cannot establish that transdermal hormone therapy is universally superior or prevents dementia. Original PMID26035291.

The requested APHRODITE/INTIMATE distinctions were not substantively supplied in the filtered Consensus response. The examined APHRODITE original supports modest sexual-function benefit in baseline diagnosed HSDD at the tested higher patch dose, alongside dose and safety limits. The indication is not transferred to energy, cognition or muscle in all women. Original PMID18987368.

The observed Consensus response does not adjudicate the requested testosterone cognitive originals. Selected original Methods/Results of the dose-response trial document verified hormone exposure and no significant benefit across tested cognitive domains, with small complete-data groups. This bounds broad cognitive claims without declaring every dose/formulation ineffective. Original PMID25430996.

Independent primary examination preserves the randomized verbal-learning signal that a uniformly negative summary would omit. Other cognitive tasks and general wellbeing did not improve in the same trial. This is a bounded task result with a mapped domain boundary, not evidence of generalized brain protection. Original PMID24716847.

The examined dose-response original finds selected muscle-power and lean-mass gains primarily at supraphysiologic exposure, while other physical-function tests did not improve. The same trial also supplies the cognitive and cardiometabolic-marker reports, so these papers are one parent study. A physiological-dose wellbeing claim cannot inherit high-exposure secondary muscle results. Original PMID24281237.

The provider discusses neurokinin alternatives, but the original OASIS3 Methods/Results verify a prespecified twelve-week primary symptom test and descriptive longer secondary outcomes with more treatment-related adverse events. That design supports a nonhormonal symptom pathway; it does not demonstrate cardiovascular prevention or lifetime safety. Original PMID40920404.

The automated provider date filter omitted the requested early thermoregulatory original. Its examined primary abstract describes randomized estradiol/placebo treatment with increased sweating threshold and reduced objectively recorded laboratory flushing. This narrows diary-only reporting bias, while its small sample and unisolated complete mediator chain remain limitations. Original PMID11872200.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Menopause Hormones: Symptoms, Prevention and Testosterone

Selected publication milestones, not an exhaustive history or discovery priority claim.

1985 — Transdermal estradiol dose experiments linked measured exposure to symptom suppression in a controlled short trial. Original PMID3928674.

1998 — PEPI compared systemic regimens and showed vasomotor relief without a matching generalized cognitive/affective benefit. Original PMID9840563.

2002 — A randomized laboratory experiment tested the predicted sweating-threshold response using physiological symptom recording. Original PMID11872200.

2002 — WHI combined-regimen prevention outcomes forced separation of symptom relief from chronic disease benefit and harm. Original PMID12117397.

2003 — WHIMS tested incident dementia in an older enrolled population rather than assuming symptom efficacy conferred brain protection. Original PMID12771112.

2008 — APHRODITE established an indication-specific testosterone counterexample: modest HSDD benefit without concomitant estrogen. Original PMID18987368.

2014 — MsFLASH directly compared estradiol, venlafaxine and placebo for baseline bothersome vasomotor symptoms. Original PMID24861828.

2014 — A selective verbal-learning testosterone signal remained bounded by null cognitive domains and general wellbeing. Original PMID24716847.

2016 — ELITE showed why early-start surrogate vascular changes and hard disease prevention must be distinguished. Original PMID27028912.

2018 — REPLENISH evaluated a defined oral estradiol/progesterone capsule with symptom and finite endometrial endpoints. Original PMID29889748.

2024 — A tested fezolinetant regimen failed to outperform placebo in MOONLIGHTI, mapping a nonhormonal context limit. Original PMID38818888.

2025 — OASIS3 expanded contemporary neurokinin-pathway symptom evidence while separating confirmatory and descriptive follow-up endpoints. Original PMID40920404.

Research gaps

The complete endocrine-to-thermoregulatory mediator sequence is not isolated by ordinary efficacy trials.

Allocation-guess assessment and objective symptom sensing are incompletely integrated in large hormone trials.

Long-term hard endpoints for contemporary transdermal estradiol/micronized progesterone begun near menopause need direct assessment rather than extrapolation from oral CEE/MPA or observational continuation.

Physiological-dose testosterone requires replicated patient-important nonspecific cognition, fatigue and muscle-function endpoints; supraphysiologic dose signals do not establish ordinary replacement benefit.

Rare breast, vascular and liver harms require formulation-specific long-term surveillance and cannot be excluded by small short trials.

Boundary experiment

Run a prospectively registered, adequately powered symptomatic-menopause trial of a measured systemic estradiol regimen, placebo and a mechanistically distinct nonhormonal comparator, with identical contact, allocation-guess checks, objective thermal/skin-conductance sensing and daily patient-important symptoms. Embed baseline-defined age/stage and route strata and a blinded randomized-withdrawal phase; test the hypothesized mediator without conditioning on response. A separate long-horizon contemporary-regimen prevention trial is required for SC3.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks. Reference PMIDs verified against PubMed metadata: 68/68 resolve to the stated first author, title, journal and year (64 numbered reference rows plus the 4 attached erratum identifiers). Retraction and expression-of-concern screen: none found; five parent records carry attached errata or comments, all recorded as status flags rather than as extra ledger rows, which is the v5.2 rule. Load-bearing claims spot-checked against the primary abstracts: 15, prioritising every benefit and harm statement that bears on a treatment decision. Scoring logic re-derived against the framework reference and SKILL.md (hard caps first, pre-registered primary-subclaim aggregation, the independence basis for the headline, the boundary check, and the M/S/D artifacts). Internal consistency checked between AT A GLANCE, the subclaim matrix, the final-score block and the score card.

Benefit-and-risk accuracy (treatment-relevant). The review states no numeric effect size anywhere in its prose, so no absolute-versus-relative conversion error is possible. Every direction, population and endpoint claim checked matched its source: WHIMS probable dementia increased on conjugated equine estrogen plus medroxyprogesterone acetate in women enrolled at age 65 or older (PMID 12771112); APHRODITE's satisfying-episode benefit at 300 micrograms per day but not at 150 micrograms per day, with the four breast-cancer diagnoses left unresolved (PMID 18987368); the transdermal-estrogen testosterone trial improving desire while its satisfying-event endpoint was not significant (PMID 16735935); MsFLASH showing both estradiol and venlafaxine beating placebo with an imprecise active-active difference (PMID 24861828); ELITE's effect confined to carotid intima-media thickness with no coronary-CT difference (PMID 27028912); REPLENISH's dose-specific symptom benefit and its bounded endometrial-safety population (PMID 29889748); and the testosterone dose-response muscle gains occurring in the 25 mg (supraphysiologic) arm only (PMID 24281237). The separation of symptom efficacy (SC2, level Zeta) from disease prevention (SC3, Beta) and from the testosterone indications (SC4 Epsilon, SC5 Gamma) is faithful to the sources.

Rejected findings (checked, no change).

1. The headline's independence hinge. The strongest available objection is that the two causal lines carrying SC2, blinded symptom-allocation trials and the predicted thermoregulatory response, share one perturbation modality (systemic estrogen), so a single systematic error about estrogen pharmacology could defeat both; under "three replications of one line make a confident Epsilon, not a Zeta" that would put SC2 and the headline one rung lower. Rejected. The framework's own list of differences that do establish independence includes "a prediction derived from the mechanism that could have failed and did not, tested by an instrument unrelated to the one that generated the mechanism"; the sweating-threshold and skin-conductance prediction (PMIDs 11872200, 10411797, 15772562) is instrumentally unrelated to the symptom diary that generated the clinical line, and the review states the residual shared failure mode rather than concealing it. The framework text does not force a change, and the steelman already argues this case and names its blocker. Flagged for the lead as the most contestable judgement in the review.
2. Citation years. References [4], [28], [29], [32], [33] and [34] print a year one later than the PubMed e-pub year. Rejected per the standing print-versus-e-pub convention.
3. Fused PMID labels in prose ("PMID24861828", "PMIDs10993030,16735941"). Consistent throughout this document and its siblings; treated as house style rather than the "randomize3808" rendering class, and left unchanged.
4. Collective-author defect, empty DOI fields, retrieval handles. Screened for; none present. All 64 ledger rows carry a resolvable PMID and DOI.
5. Aggregation. The pre-registered rule is primary-subclaim, SC2 is named explicitly, both alternatives are reported (weakest-link Beta, scope-matched Zeta), and no Epsilon subclaim is used to set the headline. Arithmetic and derivation wording both check out.
6. Rubric adaptation. Routing a menopause treatment claim through the metabolism and aging rubric leaves every quoted threshold criterion speaking about lifespan, which reads oddly. The review declares the adaptation prospectively, quotes the literal criteria unchanged, and states the substitution, which is the framework's prescribed response to a rubric gap. No change.

Residual limitations. Two corrections in this pass (AR-4, AR-5) came from systematic artifacts reported by the lead mid-pass and were applied after the first three. The shipped validator is version 2.4 and enforces the v5.4 lay-summary requirement; this package is a v5.3 review and therefore returns one FAIL, the missing lay summary, both before and after this pass. That FAIL is a framework-version mismatch rather than a defect in the review, and no lay summary was fabricated to clear it. Access depth is unchanged: 8 partial-body examinations and 56 bounded abstract or status examinations, so numeric claims inside full texts and supplements remain unaudited. The independence judgement in rejected finding 1 is a defensible call rather than a settled one.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

REFERENCES

1. Stevenson JC, Ren M, Kahler E et al. Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population. Maturitas. 2024. PMID 39317030. DOI: 10.1016/j.maturitas.2024.108117. Access: abstract_metadata. Study: UltraLow-E2Dydrogesterone-China-CTR20160689.

2. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause (New York, N.Y.). 2000. PMID 10993030. DOI: 10.1097/00042192-200007050-00005. Access: abstract_metadata. Study: PMID10993030.

3. Speroff L, Haney AF, Gilbert RD et al. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms. Menopause (New York, N.Y.). 2006. PMID 16735941. DOI: 10.1097/01.gme.0000182802.06762.b2. Access: abstract_metadata. Study: PMID16735941.

4. Ren M, Ruan X, Gu L et al. Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China. Climacteric : the journal of the International Menopause Society. 2022. PMID 34402360. DOI: 10.1080/13697137.2021.1956894. Access: abstract_metadata. Study: UltraLow-E2Dydrogesterone-China-CTR20160689.

5. Greendale GA, Reboussin BA, Hogan P et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstetrics and gynecology. 1998. PMID 9840563. DOI: 10.1016/s0029-7844(98)00305-6. Access: abstract_metadata. Study: PMID9840563.

6. Steingold KA, Laufer L, Chetkowski RJ et al. Treatment of hot flashes with transdermal estradiol administration. The Journal of clinical endocrinology and metabolism. 1985. PMID 3928674. DOI: 10.1210/jcem-61-4-627. Access: abstract_metadata. Study: PMID3928674.

7. Simon JA, Kaunitz AM, Kroll R et al. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause (New York, N.Y.). 2019. PMID 30489424. DOI: 10.1097/GME.0000000000001271. Access: abstract_metadata. Study: REPLENISH-NCT01942668.

8. Kagan R, Constantine G, Kaunitz AM et al. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women. Menopause (New York, N.Y.). 2018. PMID 30586005. DOI: 10.1097/GME.0000000000001278. Access: abstract_metadata. Study: REPLENISH-NCT01942668.

9. Hays J, Ockene JK, Brunner RL et al. Effects of estrogen plus progestin on health-related quality of life. The New England journal of medicine. 2003. PMID 12642637. DOI: 10.1056/NEJMoa030311. Access: abstract_metadata. Study: WHI-EplusP.

10. Purdie DW, Empson JA, Crichton C et al. Hormone replacement therapy, sleep quality and psychological wellbeing. British journal of obstetrics and gynaecology. 1995. PMID 7547766. DOI: 10.1111/j.1471-0528.1995.tb11433.x. Access: abstract_metadata. Study: PMID7547766.

11. Pinkerton JV, Pickar JH, Ryan KA et al. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials. Menopause (New York, N.Y.). 2016. PMID 27163519. DOI: 10.1097/GME.0000000000000617. Access: abstract_metadata. Study: PMID27163519.

12. Ockene JK, Barad DH, Cochrane BB et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA. 2005. PMID 16014592. DOI: 10.1001/jama.294.2.183. Access: abstract_metadata. Study: WHI-EplusP.

13. Huang AJ, Grady D, Jacoby VL et al. Persistent hot flushes in older postmenopausal women. Archives of internal medicine. 2008. PMID 18443259. DOI: 10.1001/archinte.168.8.840. Access: abstract_metadata. Study: PMID18443259.

14. Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013. PMID 24084921. DOI: 10.1001/jama.2013.278040. Access: full_text_partial. Study: WHI-two-parent-trials.

15. Rossouw JE, Aragaki AK, Manson JE et al. Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA internal medicine. 2025. PMID 40952729. DOI: 10.1001/jamainternmed.2025.4510. Access: abstract_metadata. Study: WHI-two-parent-trials.

16. Coker LH, Hogan PE, Bryan NR et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. Neurology. 2009. PMID 19139363. DOI: 10.1212/01.wnl.0000339036.88842.9e. Access: abstract_metadata. Study: WHI-two-parent-trials.

17. Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ (Clinical research ed.). 2007. PMID 17626056. DOI: 10.1136/bmj.39266.425069.AD. Access: abstract_metadata. Study: PMID17626056.

18. Panay N, Al-Azzawi F, Bouchard C et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric : the journal of the International Menopause Society. 2010. PMID 20166859. DOI: 10.3109/13697131003675922. Access: abstract_metadata. Study: PMID20166859.

19. Davis SR, Moreau M, Kroll R et al. Testosterone for low libido in postmenopausal women not taking estrogen. The New England journal of medicine. 2008. PMID 18987368. DOI: 10.1056/NEJMoa0707302. Access: abstract_metadata. Study: PMID18987368.

20. Buster JE, Kingsberg SA, Aguirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstetrics and gynecology. 2005. PMID 15863529. DOI: 10.1097/01.AOG.0000158103.27672.0d. Access: abstract_metadata. Study: INTIMATE-SM2.

21. Simon J, Braunstein G, Nachtigall L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. The Journal of clinical endocrinology and metabolism. 2005. PMID 16014407. DOI: 10.1210/jc.2004-1747. Access: abstract_metadata. Study: INTIMATE-SM1.

22. Shifren JL, Davis SR, Moreau M et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause (New York, N.Y.). 2006. PMID 16932240. DOI: 10.1097/01.gme.0000243567.32828.99. Access: abstract_metadata. Study: PMID16932240.

23. Nachtigall L, Casson P, Lucas J et al. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2011. PMID 21142609. DOI: 10.3109/09513590.2010.487597. Access: abstract_metadata. Study: INTIMATE-surgical-pooled-parent-reports.

24. El-Hage G, Eden JA, Manga RZ. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. Climacteric : the journal of the International Menopause Society. 2007. PMID 17653960. DOI: 10.1080/13697130701364644. Access: abstract_metadata. Study: PMID17653960.

25. Kingsberg S, Shifren J, Wekselman K et al. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. The journal of sexual medicine. 2007. PMID 17627745. DOI: 10.1111/j.1743-6109.2007.00526.x. Access: abstract_metadata. Study: INTIMATE-surgical-pooled-parent-reports.

26. Davis SR, van der Mooren MJ, van Lunsen RH et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause (New York, N.Y.). 2006. PMID 16735935. DOI: 10.1097/01.gme.0000179049.08371.c7. Access: abstract_metadata. Study: PMID16735935.

27. Braunstein GD, Sundwall DA, Katz M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Archives of internal medicine. 2005. PMID 16043675. DOI: 10.1001/archinte.165.14.1582. Access: abstract_metadata. Study: PMID16043675.

28. Glynne S, Kamal A, Kamel AM et al. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Archives of women's mental health. 2025. PMID 39283522. DOI: 10.1007/s00737-024-01513-6. Access: abstract_metadata. Study: PMID39283522.

29. Möller MC, Rådestad AF, von Schoultz B et al. Effect of estrogen and testosterone replacement therapy on cognitive fatigue. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013. PMID 23095007. DOI: 10.3109/09513590.2012.730568. Access: abstract_metadata. Study: Testosterone-estrogen-oophorectomy-50women.

30. Möller MC, Bartfai AB, Rådestad AF. Effects of testosterone and estrogen replacement on memory function. Menopause (New York, N.Y.). 2010. PMID 20555288. DOI: 10.1097/gme.0b013e3181dc2e40. Access: abstract_metadata. Study: Testosterone-estrogen-oophorectomy-50women.

31. Davis SR, Jane F, Robinson PJ et al. Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. Clinical endocrinology. 2014. PMID 24716847. DOI: 10.1111/cen.12459. Access: abstract_metadata. Study: PMID24716847.

32. Kocoska-Maras L, Zethraeus N, Rådestad AF et al. A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. Fertility and sterility. 2011. PMID 20667535. DOI: 10.1016/j.fertnstert.2010.05.062. Access: abstract_metadata. Study: Testosterone-estrogen-cognition-200women.

33. Kocoska-Maras L, Rådestad AF, Carlström K et al. Cognitive function in association with sex hormones in postmenopausal women. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013. PMID 22967437. DOI: 10.3109/09513590.2012.705385. Access: abstract_metadata. Study: Testosterone-estrogen-cognition-200women.

34. Huang G, Wharton W, Travison TG et al. Effects of testosterone administration on cognitive function in hysterectomized women with low testosterone levels: a dose-response randomized trial. Journal of endocrinological investigation. 2015. PMID 25430996. DOI: 10.1007/s40618-014-0213-3. Access: full_text_partial. Study: Testosterone-dose-response-NCT00494208.

35. Shah S, Bell RJ, Savage G et al. Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. Menopause (New York, N.Y.). 2006. PMID 16837882. DOI: 10.1097/01.gme.0000227333.50867.4e. Access: abstract_metadata. Study: PMID16837882.

36. Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertility and sterility. 2002. PMID 11872200. DOI: 10.1016/s0015-0282(01)03009-6. Access: abstract_metadata. Study: PMID11872200.

37. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. American journal of obstetrics and gynecology. 1999. PMID 10411797. DOI: 10.1016/s0002-9378(99)70437-0. Access: abstract_metadata. Study: PMID10411797.

38. Freedman RR, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters. Menopause (New York, N.Y.). 2005. PMID 15772562. DOI: 10.1097/00042192-200512020-00009. Access: abstract_metadata. Study: PMID15772562.

39. Joffe H, White DP, Crawford SL et al. Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol. Menopause (New York, N.Y.). 2013. PMID 23481119. DOI: 10.1097/GME.0b013e31828292d1. Access: abstract_metadata. Study: PMID23481119.

40. Joffe H, Crawford S, Economou N et al. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep. Sleep. 2013. PMID 24293774. DOI: 10.5665/sleep.3244. Access: abstract_metadata. Study: PMID24293774.

41. Ben Dor R, Harsh VL, Fortinsky P et al. Effects of pharmacologically induced hypogonadism on mood and behavior in healthy young women. The American journal of psychiatry. 2013. PMID 23545794. DOI: 10.1176/appi.ajp.2012.12010117. Access: abstract_metadata. Study: PMID23545794.

42. Jayasena CN, Comninos AN, Stefanopoulou E et al. Neurokinin B administration induces hot flushes in women. Scientific reports. 2015. PMID 25683060. DOI: 10.1038/srep08466. Access: full_text_partial. Study: PMID25683060.

43. Prague JK, Roberts RE, Comninos AN et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2017. PMID 28385352. DOI: 10.1016/S0140-6736(17)30823-1. Access: abstract_metadata. Study: PMID28385352.

44. Oakley AE, Steiner RA, Chavkin C et al. κ Agonists as a novel therapy for menopausal hot flashes. Menopause (New York, N.Y.). 2015. PMID 25988798. DOI: 10.1097/GME.0000000000000476. Access: abstract_metadata. Study: PMID25988798.

45. Lederman S, Ottery FD, Cano A et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet (London, England). 2023. PMID 36924778. DOI: 10.1016/S0140-6736(23)00085-5. Access: abstract_metadata. Study: PMID36924778.

46. Panay N, Joffe H, Maki PM et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial. JAMA internal medicine. 2025. PMID 40920404. DOI: 10.1001/jamainternmed.2025.4421. Access: full_text_partial. Study: PMID40920404.

47. Johnson KA, Martin N, Nappi RE et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. The Journal of clinical endocrinology and metabolism. 2023. PMID 36734148. DOI: 10.1210/clinem/dgad058. Access: abstract_metadata. Study: PMID36734148.

48. Neal-Perry G, Cano A, Lederman S et al. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Obstetrics and gynecology. 2023. PMID 36897180. DOI: 10.1097/AOG.0000000000005114. Access: abstract_metadata. Study: PMID36897180.

49. Schaudig K, Wang X, Bouchard C et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ (Clinical research ed.). 2024. PMID 39557487. DOI: 10.1136/bmj-2024-079525. Access: abstract_metadata. Study: PMID39557487.

50. Ruan X, Bai W, Ren M et al. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I). The Journal of international medical research. 2024. PMID 38818888. DOI: 10.1177/03000605241247684. Access: abstract_metadata. Study: PMID38818888.

51. Fraser GL, Lederman S, Waldbaum A et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause (New York, N.Y.). 2020. PMID 32102086. DOI: 10.1097/GME.0000000000001510. Access: abstract_metadata. Study: PMID32102086.

52. Depypere H, Timmerman D, Donders G et al. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. The Journal of clinical endocrinology and metabolism. 2019. PMID 31415087. DOI: 10.1210/jc.2019-00677. Access: abstract_metadata. Study: PMID31415087.

53. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002. PMID 12117397. DOI: 10.1001/jama.288.3.321. Access: abstract_metadata. Study: WHI-EplusP.

54. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004. PMID 15082697. DOI: 10.1001/jama.291.14.1701. Access: abstract_metadata. Study: WHI-CEEalone.

55. Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003. PMID 12771112. DOI: 10.1001/jama.289.20.2651. Access: abstract_metadata. Study: WHI-EplusP.

56. Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004. PMID 15213206. DOI: 10.1001/jama.291.24.2947. Access: abstract_metadata. Study: WHI-CEEalone.

57. Hodis HN, Mack WJ, Henderson VW et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. The New England journal of medicine. 2016. PMID 27028912. DOI: 10.1056/NEJMoa1505241. Access: full_text_partial. Study: ELITE-NCT00114517.

58. Henderson VW, St John JA, Hodis HN et al. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. Neurology. 2016. PMID 27421538. DOI: 10.1212/WNL.0000000000002980. Access: abstract_metadata. Study: ELITE-NCT00114517.

59. Gleason CE, Dowling NM, Wharton W et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS medicine. 2015. PMID 26035291. DOI: 10.1371/journal.pmed.1001833. Access: full_text_partial. Study: KEEPS-NCT00154180.

60. Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses. Menopause (New York, N.Y.). 2024. PMID 38595196. DOI: 10.1097/GME.0000000000002335. Access: abstract_metadata. Study: PMID38595196.

61. Joffe H, Guthrie KA, LaCroix AZ et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA internal medicine. 2014. PMID 24861828. DOI: 10.1001/jamainternmed.2014.1891. Access: full_text_partial. Study: PMID24861828.

62. Lobo RA, Archer DF, Kagan R et al. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. Obstetrics and gynecology. 2018. PMID 29889748. DOI: 10.1097/AOG.0000000000002645. Access: abstract_metadata. Study: REPLENISH-NCT01942668.

63. Huang G, Basaria S, Travison TG et al. Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause (New York, N.Y.). 2014. PMID 24281237. DOI: 10.1097/GME.0000000000000093. Access: full_text_partial. Study: Testosterone-dose-response-NCT00494208.

64. Huang G, Tang E, Aakil A et al. Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial. The Journal of clinical endocrinology and metabolism. 2014. PMID 24712568. DOI: 10.1210/jc.2013-4160. Access: abstract_metadata. Study: Testosterone-dose-response-NCT00494208.

Source-specific evidence cards

[1] Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population.

Shows: A pooled Europe/China randomized dataset shows fewer hot flushes with ultra-low estradiol/dydrogesterone than placebo.

Does not show: Pooled report includes the Chinese parent trial; not an independent new intervention or long-term safety test.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[2] Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol.

Shows: Randomized oral estradiol at two doses reduced hot-flush frequency compared with placebo over twelve weeks.

Does not show: Selected clinical trial populations and short follow-up do not establish cardiovascular or dementia prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[3] Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.

Shows: Two placebo-controlled oral estradiol acetate trials show dose-dependent timing and magnitude of symptom relief.

Does not show: Two trials share formulation and diary instruments; higher dose does not prove all-regimen superiority or safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[4] Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China.

Shows: A Chinese randomized trial shows ultra-low estradiol/dydrogesterone reduces daily hot flushes more than placebo.

Does not show: Placebo improved substantially; twelve-week symptom benefit is not disease prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[5] Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial.

Shows: PEPI hormone regimens reduce vasomotor symptoms while anxiety, cognitive and affective checklist outcomes show no treatment difference.

Does not show: Multiple hormone regimens belong to one parent trial and symptom instruments cannot establish dementia prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[6] Treatment of hot flashes with transdermal estradiol administration.

Shows: Randomized transdermal estradiol produced exposure-dependent hot-flush suppression at tested doses.

Does not show: Small early trial and regression predictions are not validated individual response thresholds or long-term safety evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[7] Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.

Shows: REPLENISH participants reported improved menopause-specific quality of life and vasomotor domain scores with several oral estradiol/progesterone doses.

Does not show: Secondary outcomes and correlations do not prove mediation; this is the same parent trial as its sleep report.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[8] Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.

Shows: REPLENISH oral estradiol/progesterone improved several self-reported sleep outcomes compared with placebo.

Does not show: Sleep was secondary and subjective; improvements do not establish all sleep disorders are hormone mediated.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[9] Effects of estrogen plus progestin on health-related quality of life.

Shows: WHI combined therapy relieved vasomotor symptoms in younger symptomatic women but did not improve general quality of life meaningfully overall.

Does not show: Older prevention cohort differs from modern symptom-selected users; several endpoints and subgroups require caution.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[10] Hormone replacement therapy, sleep quality and psychological wellbeing.

Shows: A small single-blind trial improved menopausal symptoms without measured polysomnographic sleep improvement.

Does not show: Limited size and single blinding constrain inference; symptom relief need not normalize every sleep parameter.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[11] Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.

Shows: SMART pooled minority/white subgroup analyses show symptom improvement with conjugated estrogens/bazedoxifene.

Does not show: Post hoc pooling and modest minority representation do not establish ethnic equivalence or independent replication per report.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[12] Symptom experience after discontinuing use of estrogen plus progestin.

Shows: Former WHI combined-hormone users reported more vasomotor symptoms after study-pill cessation than former placebo users.

Does not show: Selected continuing users and post-stop unblinding limit causal withdrawal inference and independence from WHI allocation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[13] Persistent hot flushes in older postmenopausal women.

Shows: Some older women have persistent hot flushes, associated with baseline clinical factors but not measured estradiol concentration.

Does not show: Observational associations do not isolate withdrawal causality or identify an outcome-independent hormone responder group.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[14] Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Shows: Extended WHI analyses retain vasomotor benefit but divergent clinical risks and benefits; neither regimen improved overall mortality.

Does not show: Two parent randomized trials generate many reports; oral CEE regimens cannot be transferred wholesale to other routes or younger indications.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph2, 2:RESULTS:paragraph24, 2:RESULTS:paragraph27, 2:RESULTS:paragraph29, 2:RESULTS:paragraph35, 2:RESULTS:paragraph37. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[15] Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials.

Shows: The WHI symptom/CVD secondary analysis reports age- and regimen-dependent clinical and symptom effects.

Does not show: Two attached corrections concern text/supplement and Figure 3; quantitative reliance is withheld pending their details, and subgroup analyses are not new trials.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID41182785; ErratumIn: PMID41396618. Subclaims: SC2, SC3.

[16] Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study.

Shows: WHIMS-MRI found no significant hormone-allocation difference in ischemic lesion volumes despite clinical cognitive concerns.

Does not show: Post-trial MRI participants were selected; this proxy null neither proves brain protection nor explains every dementia mechanism.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[17] Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.

Shows: WISDOM found more cardiovascular and thromboembolic events with combined therapy started many years after menopause.

Does not show: Premature closure and brief follow-up limit cancer, dementia and early-initiation conclusions.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[18] Testosterone treatment of HSDD in naturally menopausal women: the ADORE study.

Shows: ADORE found improved satisfying sexual events, desire and distress with a testosterone patch in naturally menopausal HSDD women.

Does not show: Selected diagnosed HSDD and six-month outcomes do not establish general cognition, energy or long-term safety benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[19] Testosterone for low libido in postmenopausal women not taking estrogen.

Shows: APHRODITE found modest sexual-function benefit at the higher tested testosterone patch dose in postmenopausal HSDD women without estrogen.

Does not show: Lower dose missed the event-frequency endpoint; androgenic events increased and rare breast outcomes cannot settle long-term risk.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[20] Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial.

Shows: A randomized patch trial improved sexual activity, desire and distress after surgical menopause with concomitant estrogen.

Does not show: The indicated population and short exposure do not establish nonspecific enhancement or lifelong safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[21] Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder.

Shows: INTIMATE SM1 improved satisfying sexual activity and desire and reduced distress versus placebo after surgical menopause.

Does not show: Patient-reported endpoints, concurrent estrogen and sponsor-related trial platform constrain mechanistic independence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[22] Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study.

Shows: INTIMATE NM1 reported improved sexual events, desire and distress in naturally menopausal HSDD women taking estrogen.

Does not show: An attached erratum is recorded without identifier; baseline SHBG analytic restriction and short follow-up limit inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC4.

[23] Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen.

Shows: Open-label extensions reported no major worsening of common safety measures during testosterone patch exposure.

Does not show: Selected continuing participants and lack of randomized long-term comparator cannot exclude rare breast or cardiovascular harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[24] A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder.

Shows: A testosterone cream crossover trial improved sexual domains in HSDD women but not mood or energy.

Does not show: Small sample, concurrent estrogen and crossover limitations do not establish broad cognitive or muscle benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4, SC5.

[25] Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.

Shows: An interviewed subset of two testosterone trials reported meaningful sexual benefit more often on active patches.

Does not show: Selected interviews and responder analyses are not an independent trial or a baseline definition of who benefits.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[26] Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.

Shows: Testosterone patch improved desire with transdermal estrogen after oophorectomy, while the sexual-event endpoint was not significant.

Does not show: Small sample and incomplete retention limit precision; author-name correction is attached and not a new source.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID not supplied. Subclaims: SC4.

[27] Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.

Shows: A dose-ranging patch trial found sexual-domain benefit at an intermediate dose, with lower-dose nulls and no consistent monotonic response.

Does not show: Substantial attrition and marginal endpoint significance weaken precise dose-response prediction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[28] Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study.

Shows: A retrospective menopause-clinic cohort reported mood and cognitive symptom improvement after testosterone addition.

Does not show: No randomized comparator; expectation, regression, concurrent HRT and selective treatment seeking prevent causal generalization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[29] Effect of estrogen and testosterone replacement therapy on cognitive fatigue.

Shows: A surgical-menopause crossover trial found no cognitive-fatigue benefit from testosterone added to estrogen.

Does not show: Small sample and a specific oral regimen cannot exclude every formulation effect; same parent as memory analysis.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[30] Effects of testosterone and estrogen replacement on memory function.

Shows: Testosterone added to estrogen worsened immediate verbal memory while other memory outcomes were unaffected.

Does not show: Small surgical-menopause trial and multiple domains do not prove all testosterone regimens impair cognition.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[31] Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy.

Shows: A randomized transdermal testosterone trial improved its verbal-learning task but not other cognitive domains or general wellbeing.

Does not show: One modest task-specific signal is neither prevention of dementia nor evidence of generalized energy and muscle benefits.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[32] A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women.

Shows: A randomized estrogen/testosterone/placebo trial found no substantial four-week differences in verbal or spatial cognition.

Does not show: Short duration and oral regimens do not settle longer transdermal exposure or dementia endpoints.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[33] Cognitive function in association with sex hormones in postmenopausal women.

Shows: Secondary hormone-level analyses found domain-specific associations in the same randomized cohort.

Does not show: Correlations among post-treatment hormones and scores do not manipulate a mediator or add an independent efficacy trial.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[34] Effects of testosterone administration on cognitive function in hysterectomized women with low testosterone levels: a dose-response randomized trial.

Shows: A testosterone dose-ranging trial found no benefit across tested cognitive domains over twenty-four weeks despite verified exposure.

Does not show: Only participants with complete cognitive data were analyzed; small dose groups limit precision and share a parent with muscle outcomes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph2, 1:Methods:paragraph4, 2:Results:paragraph0, 2:Results:paragraph3. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[35] Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial.

Shows: Aromatase inhibition did not alter cognition in estrogen-treated women receiving testosterone in both randomized arms.

Does not show: Without a testosterone-free randomized arm, within-group improvement cannot establish testosterone efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[36] Estrogen raises the sweating threshold in postmenopausal women with hot flashes.

Shows: Randomized estradiol raised sweating threshold and reduced objectively recorded laboratory hot flashes compared with placebo.

Does not show: Small physiological trial narrows diary expectation but does not prove the complete estrogen–KNDy mediator sequence or all individual responses.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[37] Reduced thermoregulatory null zone in postmenopausal women with hot flashes.

Shows: Controlled heating/cooling and exercise showed narrowed thermoregulatory zones and heat-triggered flushing in symptomatic women.

Does not show: Exposure groups were not randomized for estrogen deficiency; this is thermoregulatory discrimination, not proof estrogen alone causes all symptoms.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[38] Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters.

Shows: Symptomatic women had lower sweating thresholds and greater sweat rates than asymptomatic/eumenorrheic groups despite similar explanatory hormone levels.

Does not show: Small nonrandomized groups support a thermoregulatory phenotype but not an exclusive sex-steroid cause.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[39] Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol.

Shows: GnRH agonist-induced ovarian suppression produced new hot flashes, with objective and subjective sleep effects differing by measurement.

Does not show: Uncontrolled induction and post-outcome symptom grouping do not isolate estrogen from all GnRH effects or prove every sleep problem is vasomotor.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[40] A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep.

Shows: A GnRH-agonist model associated induced nighttime hot flashes with greater polysomnographic sleep fragmentation.

Does not show: Within-experiment symptom correlations are not an independently randomized mediator; related clinical protocol may share participants and instruments.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[41] Effects of pharmacologically induced hypogonadism on mood and behavior in healthy young women.

Shows: Induced hypogonadism increased nighttime hot flashes and disturbed sleep but rarely clinically significant depressive symptoms in screened healthy women.

Does not show: No placebo induction group; psychiatric-history exclusions prevent transfer to women with prior mood disorders.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[42] Neurokinin B administration induces hot flushes in women.

Shows: Blinded neurokinin-B infusion caused flushing with objective heat-dissipation changes in healthy women without measured estradiol change.

Does not show: Exogenous challenge is a pathway sufficiency test, not proof hormone withdrawal or endogenous NKB is necessary in every menopausal flush.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph2, 0:Methods:paragraph5, 0:Methods:paragraph6, 1:Results:paragraph3, 1:Results:paragraph4, 1:Results:paragraph7. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[43] Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial.

Shows: A blinded NK3-antagonist crossover trial reduced menopausal hot-flush frequency compared with placebo.

Does not show: Small sample, incomplete completion and liver-enzyme elevations limit broad efficacy and safety predictions; it tests a nonhormonal pathway.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[44] κ Agonists as a novel therapy for menopausal hot flashes.

Shows: An acute kappa-agonist pilot reduced hot-flash frequency relative to placebo in a small crossover sample.

Does not show: Very small analyzed group, acute exposure and opioid subjective effects limit blinding and long-term causal interpretation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[45] Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.

Shows: SKYLIGHT1 found reduced vasomotor frequency/severity with fezolinetant at tested doses during its placebo-controlled interval.

Does not show: Nonhormonal efficacy does not prove systemic MHT prevention or necessity; later extension lacks ongoing placebo comparison.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[46] Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.

Shows: OASIS3 elinzanetant reduced its prespecified twelve-week vasomotor-frequency endpoint; later symptoms favored treatment descriptively.

Does not show: Longer secondary/exploratory endpoints were not powered confirmatory tests, and treatment-related adverse events were more frequent.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph1, 1:Methods:paragraph4, 1:Methods:paragraph8, 2:Results:paragraph10, 2:Results:paragraph11, 2:Results:paragraph13. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[47] Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.

Shows: SKYLIGHT2 reproduced fezolinetant vasomotor-frequency and severity benefits during placebo-controlled treatment.

Does not show: Same pharmacological class and diary platform are replication rather than a new independent causal modality.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[48] Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.

Shows: SKYLIGHT4 characterized one-year endometrial, liver and bone safety under randomized fezolinetant exposure.

Does not show: Safety-focused endpoints are not evidence of estrogen replacement efficacy or an assurance against rare postmarketing liver injury.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[49] Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.

Shows: DAYLIGHT reduced hot-flush frequency/severity and sleep disturbance in women considered unsuitable for hormone therapy.

Does not show: Most participants were averse or caution categories rather than contraindicated; attached correction and finite follow-up constrain safety generalization.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID39603693. Subclaims: SC1.

[50] Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).

Shows: MOONLIGHTI found no significant vasomotor-frequency or severity advantage for the tested fezolinetant dose in East Asian women.

Does not show: A regimen/context null restricts generalization but does not erase positive trials at other doses or populations.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[51] A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.

Shows: VESTA dose-ranging NK3 blockade improved vasomotor frequency at tested doses and severity at some regimens.

Does not show: Multiple dose arms share one study; diary responses and variable severity results constrain precise prediction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[52] Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.

Shows: A fezolinetant phase2a placebo-controlled trial reduced vasomotor score and reported frequency.

Does not show: Small selected cohort and one regimen do not establish universal response or lifetime safety.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[53] Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Shows: WHI combined oral CEE/MPA had an unfavorable overall prevention risk–benefit balance despite fracture benefits.

Does not show: Regimen and enrollment ages matter; results do not refute symptom efficacy or establish the risk of every modern formulation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[54] Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Shows: WHI CEE-alone increased stroke risk, reduced hip fractures and did not demonstrate coronary prevention or overall net benefit.

Does not show: Hysterectomy cohort and oral CEE cannot be treated as the same population/regimen as combined therapy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[55] Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Shows: WHIMS combined therapy increased probable dementia in women enrolled aged at least sixty-five and did not prevent mild cognitive impairment.

Does not show: Age and CEE/MPA regimen limit extrapolation to early-menopause modern therapy; dementia is distinct from acute cognitive tests.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[56] Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Shows: WHIMS estrogen-alone did not reduce dementia or mild cognitive impairment, and pooled trials showed increased risk.

Does not show: The estrogen-alone dementia estimate was imprecise; pooled WHI reports are not extra independent studies.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[57] Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.

Shows: ELITE slowed carotid intima-media progression only with early estradiol initiation, without corresponding coronary CT differences.

Does not show: Surrogate progression and sparse clinical events do not establish net cardiovascular or dementia prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph0, 0:METHODS:paragraph2, 0:METHODS:paragraph5, 0:METHODS:paragraph6, 1:RESULTS:paragraph2, 1:RESULTS:paragraph3, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[58] Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis.

Shows: ELITE cognitive outcomes showed no verbal-memory, executive or global-cognition benefit with early or later estradiol initiation.

Does not show: Several years of cognitive tests cannot exclude later dementia prevention; same parent as the vascular report.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[59] Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study.

Shows: KEEPS showed vasomotor relief but no cognitive benefit; oral CEE improved selected mood scores while transdermal estradiol did not.

Does not show: Cognitively healthy low-risk recent-menopause users, attrition and finite horizon constrain disease-prevention inference.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph4, 1:Methods:paragraph6, 1:Methods:paragraph8, 1:Methods:paragraph22, 2:Results:paragraph1, 2:Results:paragraph4, 2:Results:paragraph12, 2:Results:paragraph14. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[60] Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses.

Shows: Large Medicare analyses associate certain hormone formulations/routes with lower mortality and selected disease risks after age sixty-five.

Does not show: Healthy-user, prescribing, continuation and confounding-by-indication effects remain; sample size does not randomize exposure.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[61] Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial.

Shows: MsFLASH randomized estradiol and venlafaxine both reduced bothersome vasomotor frequency more than placebo.

Does not show: The between-active-treatment contrast was imprecise; short follow-up cannot establish general hormone superiority or disease prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph3, 1:METHODS:paragraph6, 1:METHODS:paragraph8, 2:RESULTS:paragraph1, 2:RESULTS:paragraph2, 2:RESULTS:paragraph3. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[62] A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

Shows: REPLENISH tested oral estradiol/progesterone versus placebo and found vasomotor-frequency/severity benefit at several doses.

Does not show: Dose-specific coprimary results and finite endometrial analysis population do not prove zero lifetime risk; attached correction details require separate checking.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID30134411. Subclaims: SC2.

[63] Testosterone dose-response relationships in hysterectomized women with or without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial.

Shows: Testosterone dose-ranging produced lean-mass and selected muscle-power gains mainly at supraphysiologic exposure, with several physical-function tests unchanged.

Does not show: Small dose groups, secondary outcomes and late trial registration limit prediction; high-dose gains cannot establish physiological replacement benefit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:METHODS:paragraph0, 1:METHODS:paragraph1, 1:METHODS:paragraph3, 1:METHODS:paragraph6, 1:METHODS:paragraph7, 2:RESULTS:paragraph3, 2:RESULTS:paragraph6, 2:RESULTS:paragraph7, 3:DISCUSSION:paragraph1, 3:DISCUSSION:paragraph4. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[64] Testosterone dose-response relationships with cardiovascular risk markers in androgen-deficient women: a randomized, placebo-controlled trial.

Shows: The same testosterone dose-response parent trial found no major changes in measured cardiometabolic risk markers.

Does not show: Marker stability over a short interval cannot exclude clinical cardiovascular harms or establish metabolic prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• menopause-hormone-symptoms.review.md
• menopause-hormone-symptoms.scorecard.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 64 · load-bearing claims: 70 · verified: 70 · unverified: 0 · contradicted: 0 · schema 5.3